BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1112 related articles for article (PubMed ID: 23329699)

  • 21. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions.
    Popescu BF; Guo Y; Jentoft ME; Parisi JE; Lennon VA; Pittock SJ; Weinshenker BG; Wingerchuk DM; Giannini C; Metz I; Brück W; Shuster EA; Carter J; Boyd CD; Clardy SL; Cohen BA; Lucchinetti CF
    Neurology; 2015 Jan; 84(2):148-58. PubMed ID: 25503621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of aquaporin-4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania.
    Sakalauskaitė-Juodeikienė E; Armalienė G; Kizlaitienė R; Bagdonaitė L; Giedraitienė N; Mickevičienė D; Rastenytė D; Kaubrys G; Jatužis D
    Brain Behav; 2018 Nov; 8(11):e01129. PubMed ID: 30284401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
    J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of AQP4 Antibody Serostatus and its Prediction of Visual Outcome in Neuromyelitis Optica: A Systematic Review and Meta-Analysis.
    Lin N; Liu Q; Wang X; Ma J; Li Y
    Protein Pept Lett; 2017; 24(3):245-252. PubMed ID: 28071581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuromyelitis optica and aquaporin-4 (AQP4) autoantibodies in consecutive optic neuritis patients in Southern Finland.
    Siuko M; Tienari PJ; Saastamoinen KP; Atula S; Miettinen A; Kivelä T; Setälä K
    Acta Ophthalmol; 2014 Jun; 92(4):387-91. PubMed ID: 23773223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A recurrent longitudinally extensive transverse myelitis with Aquaporin-4(AQP4) antibody after herpes zoster.
    Park JS; Hwang SJ; Shin JH; Kim DS
    J Neurol Sci; 2013 Nov; 334(1-2):69-71. PubMed ID: 23953947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.
    Juryńczyk M; Weinshenker B; Akman-Demir G; Asgari N; Barnes D; Boggild M; Chaudhuri A; D'hooghe M; Evangelou N; Geraldes R; Illes Z; Jacob A; Kim HJ; Kleiter I; Levy M; Marignier R; McGuigan C; Murray K; Nakashima I; Pandit L; Paul F; Pittock S; Selmaj K; de Sèze J; Siva A; Tanasescu R; Vukusic S; Wingerchuk D; Wren D; Leite I; Palace J
    J Neurol; 2016 Jan; 263(1):140-9. PubMed ID: 26530512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica.
    Takahashi T; Fujihara K; Nakashima I; Misu T; Miyazawa I; Nakamura M; Watanabe S; Ishii N; Itoyama Y
    Tohoku J Exp Med; 2006 Dec; 210(4):307-13. PubMed ID: 17146196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    Ungureanu A; de Seze J; Ahle G; Sellal F
    Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and radiological profile of neuromyelitis optica spectrum disorders in a Pakistani cohort.
    Rajput HM; Hassan M; Badshah M
    Mult Scler Relat Disord; 2023 Jun; 74():104656. PubMed ID: 37068371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnostic criteria and differential diagnosis of neuromyelitis optica].
    Nakashima I
    Nihon Rinsho; 2014 Nov; 72(11):1964-9. PubMed ID: 25518378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [NMO spectrum disorders and anti AQP4 antibody].
    Takai Y; Misu T; Takahashi T; Nakashima I; Fujihara K
    Brain Nerve; 2013 Apr; 65(4):333-43. PubMed ID: 23568981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS.
    Juryńczyk M; Craner M; Palace J
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):20-5. PubMed ID: 25248365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders.
    Jarius S; Franciotta D; Bergamaschi R; Wildemann B; Wandinger KP
    Clin Chem Lab Med; 2010 May; 48(5):659-63. PubMed ID: 20184532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expanded spectrum of neuromyelitis optica: evidences for a new definition.
    Lana-Peixoto MA; Callegaro D
    Arq Neuropsiquiatr; 2012 Oct; 70(10):807-13. PubMed ID: 23060108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease.
    Magaña SM; Pittock SJ; Lennon VA; Keegan BM; Weinshenker BG; Lucchinetti CF
    Arch Neurol; 2009 Aug; 66(8):964-6. PubMed ID: 19667216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.